Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Protects against apoptosis mediated by Apaf-1 (By similarity).. Additionally we are shipping Apoptosis, Caspase Activation Inhibitor Proteins (6) and Apoptosis, Caspase Activation Inhibitor Kits (1) and many more products for this protein.
Showing 10 out of 106 products:
Human Polyclonal AVEN Primary Antibody for WB - ABIN1881095
Bailey, Xie, Do, Montpetit, Diaz, Mohan, Keavney, Yusuf, Gerstein, Engert, Anand: Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study. in Diabetes Care 2010
Show all 3 references for ABIN1881095
Human Monoclonal AVEN Primary Antibody for EIA, IHC (p) - ABIN336088
Figueroa, Chen, Oyler, Hardwick, Betenbaugh: Aven and Bcl-xL enhance protection against apoptosis for mammalian cells exposed to various culture conditions. in Biotechnology and bioengineering 2004
Show all 2 references for ABIN336088
Human Polyclonal AVEN Primary Antibody for EIA, IHC (p) - ABIN499367
Lockshin, Osborne, Zakeri: Cell death in the third millennium. in Cell death and differentiation 2000
Inhibition of progesterone synthesis (trilostane treatment) resulted in changes in AVEN localization within the cumulus oocyte complex, corresponding to caspase 3 (show CASP3 Antibodies) activation and altered mitochondrial distribution.
The Aven RGG/RG motif bound G4 structures within the coding regions of the MLL1 and MLL4 (show MLL2 Antibodies) mRNAs increasing their polysomal association and translation, resulting in the induction of transcription of leukemic genes.
the expression of Aven is regulated by the Akt (show AKT1 Antibodies) signaling pathway through cathepsin D (show CTSD Antibodies) activity, which contributes to the sensitivity of cancer cells to chemotherapeutic agents.
The findings implicate Aven in ATR (show ANTXR1 Antibodies)-Chk1 (show CHEK1 Antibodies) signalling and point towards Chk1 (show CHEK1 Antibodies) inhibition as a strategy to sensitize human osteosarcomas to chemotherapy.
Overexpression of the anti-apoptotic protein AVEN contributes to increased malignancy in hematopoietic neoplasms.
a model of Aven activation by which its N-terminal inhibitory domain is removed by CathD (show CTSD Antibodies)-mediated proteolysis, thereby unleashing its cytoprotective function.
The results suggest that deregulation of the expression of the apoptosis inhibitor Aven may be related to male factor infertility.
the expression level of aven mRNA in de novo AML (show RUNX1 Antibodies) patients obviously increases
Results suggest that the regulation of Exportin-1/CRM1 (show XPO1 Antibodies)-dependent nucleocytoplasmatic traffic of Aven could modulate its ability to influence cell cycle progression.
Aven expression was found to be higher in patients >or=10 years old or <1 year, and with unfavorable cytogenetic abnormalities. It was also significantly higher in relapsed patients in the standard-risk group and an independent poor prognostic factor.
These results identify Aven as a new ATM (show ATM Antibodies) activator and describe a positive feedback loop operating between Aven and ATM (show ATM Antibodies); in aggregate, these findings place Aven, a known apoptotic inhibitor, as a critical transducer of the DNA-damage signal.
One of the cDNA clones obtained by selective PCR subtraction cloning matched two cDNA sequences in the mouse testis cDNA database, and was highly homologous to Aven, a human gene regulating cell death.
activated in irradiated tissues protected from radiodamage by treatment with recombinant superoxide dismutase (MnSOD (show SOD2 Antibodies))
Protects against apoptosis mediated by Apaf-1 (By similarity).
cell death regulator Aven
, Aven-like protein
, apoptosis, caspase activation inhibitor
, cell death regulator aven
, cell death regulator aven-like
, programmed cell death 12